

Date: 29 November 2017 Sydney, Australia

**ASX: NOX** 

**ASX Limited** 20 Bridge Street SYDNEY NSW 2000

### Noxopharm Limited

ABN 50 608 966 123

## Webcast of Noxopharm Limited 2017 Annual General Meeting

**Registered Office:** 

Suite 1 Level 6 50 Queen St Australia

Melbourne VIC 3000

Noxopharm Limited (ASX: NOX), an Australian oncology drug development company, invites shareholders and the market to visit the following link;

http://www.noxopharm.com/irm/content/presentations.aspx?RID=401

#### **Operational Office:**

Suite 3, Level 4 828 Pacific Highway Gordon NSW 2072

Australia

# for the webcast recording of the 2017 AGM Presentations.

#### >>>>>>>>>

### **Board of Directors Mr Peter Marks**

Chairman Non-Executive Director

### **Dr Graham Kelly**

**Chief Executive Officer Managing Director** 

### **Dr Ian Dixon** Non-Executive Director

## **About Noxopharm**

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of chemotherapy- and radiation-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development. The Company also has initiated a pipeline of non-oncology drugs.

### **About Nyrada Inc.**

Nyrada Inc is a recently formed, New York-based biotechnology company established to house Noxopharm non-oncology drug assets.

#### **Investor & Corporate Enquiries:**

Prue Kelly M: 0459 022 445

E: info@noxopharm.com

### **Company Secretary:**

**David Franks** T: +61 2 9299 9690 E: dfranks@fa.com.au

### www.noxopharm.com

#### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and

assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.